SNY (Sanofi) EPS (Diluted) : $1.82 (TTM As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi EPS (Diluted)?

Sanofi's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was $0.96. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.82.

Sanofi's EPS (Basic) for the six months ended in Jun. 2024 was $0.97. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.83.

Sanofi's EPS without NRI for the six months ended in Jun. 2024 was $1.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $2.98.

During the past 12 months, Sanofi's average EPS without NRIGrowth Rate was -24.80% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 2.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sanofi's highest 3-Year average EPS without NRI Growth Rate was 37.90% per year. The lowest was -18.20% per year. And the median was 8.10% per year.

Sanofi EPS (Diluted) Historical Data

The historical data trend for Sanofi's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi EPS (Diluted) Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

1.22

5.94

2.80

3.53

2.35

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Diluted)	Get a 7-Day Free Trial															1.35	2.18	1.48	0.86	0.96

Competitive Comparison of Sanofi's EPS (Diluted)

For the Drug Manufacturers - General subindustry, Sanofi's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi's PE Ratio falls into.

Sanofi EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sanofi's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(5888.768	-	0)	/	2512.800
	=	2.34

Sanofi's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(2417.653	-	0)	/	2507.600
	=	0.96

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.82

Sanofi (NAS:SNY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sanofi EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sanofi's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.